Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (34)

Menin inhibitors (MENINi) show promise for relapsed or refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 mutations (NPM1c). Outcomes after MENINi failure are poorly understood. To characterize the mutational landscape and subsequent outcomes, we conducted a multicenter retrospective study of adults from 4 US centers with R/R AML after MENINi failure (relapse after response or primary refractory). The 84 patients (63% KMT2Ar, n = 53; 23% NPM1c, n = 19) who received MENINi were heavily pretreated: 86% (n = 72) had previous intensive chemotherapy (IC) and 77% venetoclax (VEN; n = 67). After MENINi failure, 40% of patients (n = 34) received supportive care. For the treated patients (n = 50), common regimens included hypomethylating agent (HMA)/VEN (26%, n = 13), clinical trial (26%, n = 13), and gilteritinib-based therapy (18%, n = 9). The complete response (CR)/CR with incomplete hematologic recovery (CRi) rate for nontrial therapies was 19% (n = 7); overall response rate was 32% (n = 12). All CR/CRi occurred with HMA/VEN (n = 2, 15%), IC + VEN (n = 4, 67%), or MENINi switching (bleximenib to revumenib, n = 1 [50%]). No patient with FLT3-ITD mutation responded to gilteritinib (0/6 gilteritinib-naïve). Median overall survival from start of next therapy was 4.4 months and superior for patients who achieved CR/CRi, (15.4 vs 3.4 months, P = .048). Outcomes after MENINi failure are poor, but responses occur with VEN-based regimens or MENINi switching. FLT3-ITD, WT1, and MEN1 mutations are associated with resistance.

Year:

2026

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (63)

Esteban Braggio

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Montserrat Garcia-Closas

Professor of Epidemiology

Institute of Cancer Research

UNITED KINGDOM
View details

Kanika Arora

Senior Computational Biologist II

Sloan Kettering Institute

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Olivier Elemento

Professor

Weill Cornell Medical College

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jennifer Hu

Professor

University of Miami

UNITED STATES
View details

Matthew Pianko

Clinical Associate Professor

University of Michigan

UNITED STATES
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Yasmin Abaza

Assistant Professor of Medicine

Northwestern Medicine

UNITED STATES
View details

Justin Cross

Sloan Kettering Institute

UNITED STATES
View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Shiv Prakash Verma

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Sergio Giralt

Chief Attending, Adult BMT Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Brian Ball

Assistant Clinical Professor

City of Hope

UNITED STATES
View details

Giancarlo Castellano

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Louise Brinton

Branch Chief

National Cancer Institute

UNITED STATES
View details

Stefan Ambs

Senior Investigator (tenured) and Head of the Molecular Epidemiology Section

National Cancer Institute

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Alexandra Kovach

Director, Hematopathology; Associate Professor, Keck School of Medicine of University of Southern California

Children's Hospital of Los Angeles

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Urvi Shah

Assistant Attending, Myeloma Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Gunjan Shah

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Gladys Block

University of California, Berkeley

UNITED STATES
View details

Stephen Chanock

National Institutes of Health

UNITED STATES
View details

Alison Margaret Dunning

University of Cambridge

UNITED KINGDOM
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Matthew Barth

Clinical Associate Professor

University at Buffalo State University of New York School of Medicine and Biomedical Sciences

UNITED STATES
View details

Setor Amuzu

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jonathan Peled

Director

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Charles F. Lynch

-

UNITED STATES
View details

Lisa Giulino-Roth

Weill Cornell Medicine

UNITED STATES
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Gordon Watt

Junior Group Leader

The Netherlands Cancer Institute

NETHERLANDS
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Terzah Horton

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Sridevi Rajeeve

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Maximilian Merz

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Wenbin Xiao

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Craig H. Moskowitz

University of Miami Miller School of Medicine

UNITED STATES
View details

Hira Mian

-

CANADA
View details

Anita D'Souza

Medical College of Wisconsin

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Hamza Hashmi

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Jian Gu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Thomas Ahearn

Staff Scientist

National Cancer Institute

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Juan-José Garcés

Research Scholar

Sloan Kettering Institute

UNITED STATES
View details

Seth Wiafe

Assistant Professor

Loma Linda University

UNITED STATES
View details

Patrick Blaney

Senior Bioinformatics Programmer

NYU Langone Health

UNITED STATES
View details

William D Figg

Senior Investigator, Lab Chief, Associate Director

National Institutes of Health

UNITED STATES
View details